<SEC-DOCUMENT>0001178913-24-002560.txt : 20240813
<SEC-HEADER>0001178913-24-002560.hdr.sgml : 20240813
<ACCEPTANCE-DATETIME>20240813083544
ACCESSION NUMBER:		0001178913-24-002560
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20240813
FILED AS OF DATE:		20240813
DATE AS OF CHANGE:		20240813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		241198939

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2431835.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div class="BRPFPageHeader">
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">&#160;UNITED STATES&#160;</font>&#160;&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160;20549</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
      <div style="text-align: center; line-height: 1.25;">&#160;&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">of&#160;the Securities Exchange Act of 1934</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">For the month of August 2024<br>
        Commission File No.:001-35773</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">21 Ha'arba'a Street, Tel Aviv, 6473921, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.&#160;&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Form 20-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160; &#160;&#160; &#160; Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="text-indent: 14.2pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____&#160;</div>
      <div style="text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Attached hereto and incorporated herein by reference is the notice and proxy statement for the annual general meeting of shareholders of RedHill Biopharma Ltd. scheduled for September 17, 2024.<br>
        <br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No.
        333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May
        3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001) and on June 20, 2024 (File No. 333-280327), and its Registration Statements on Form F-3 filed
        with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zd4ef4892acaa464ea9f06faa7bb7f422" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="line-height: 1.25;">REDHILL BIOPHARMA LTD.</div>
            </td>
            <td style="width: 18%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="line-height: 1.25;">(the "Registrant")</div>
            </td>
            <td style="width: 18%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 27.76%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 18%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">Date: August 13, 2024</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td nowrap="nowrap" style="width: 27.76%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">/s/ Dror Ben-Asher</div>
            </td>
            <td style="width: 18%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">Name:</div>
            </td>
            <td nowrap="nowrap" style="width: 27.76%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;Dror Ben-Asher</div>
            </td>
            <td style="width: 18%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">Title:</div>
            </td>
            <td style="width: 27.76%; vertical-align: top;">
              <div style="line-height: 1.25;">Chief Executive Officer</div>
            </td>
            <td style="width: 18%; vertical-align: middle;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
  </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">REDHILL BIOPHARMA LTD.<br>
    21 Ha&#8217;arba&#8217;a Street</div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Tel-Aviv 6473921</div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Israel</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS</div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">To be held on September 17, 2024</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Annual General Meeting of Shareholders of RedHill Biopharma Ltd. (the &#8220;<u>Company</u>&#8221;), will be held at the offices of the Company, 21 Ha&#8217;arba&#8217;a Street, Tel-Aviv, Israel, on
    September 17, 2024, at 15:00 p.m. Israel time, or at any adjournments thereof (the &#8220;<u>General Meeting</u>&#8221;), for the following purposes:</div>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="zfca597f4cec84e019b576d30f216cd72" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">1.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To appoint Kesselman &amp; Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company&#8217;s auditors for the year 2024 and for an additional period until the next Annual General
            Meeting; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2023;</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="z365dc2b503c8479d9c2fd642b8326ec1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">2.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To approve the re-election of Mr. Eric Swenden and Mr. Ofer Tsimchi and approve the election of Dr. Roni Mamluk to the board of directors of the Company (the &#8220;<u>Board of Directors</u>&#8221;), each for an additional three-year term until the
            annual general meeting to be held in 2027;</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="z094bf82566a44206a6c609e298c1944e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">3.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To approve the grant of restricted share units (&#8220;<u>RSUs</u>&#8221;) each with respect to one American Depository Shares (each representing 400 ordinary shares, par value NIS 0.01 each) (&#8220;<u>ADSs</u>&#8221;) to the non-executive directors of the
            Company;</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="z05f16463b4b04994bf8eea1fc1a8964b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">4.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors; and</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="zb0fd1ec456394a9fad381b5910884a2f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">5.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company&#8217;s Chief Commercial Officer, and Director.</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, shareholders at the General Meeting will have an opportunity to review and ask questions regarding the financial statements of the Company for the fiscal year ended
    December 31, 2023.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Company is currently unaware of any other matters that may be raised at the General Meeting. Should any other matters be properly raised at the General Meeting, the persons
    designated as proxies shall vote according to their own judgment on those matters.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Only holders of record of Ordinary Shares and holders of record of ADSs, evidenced by American Depositary Receipts issued by The Bank of New York Mellon at the close of business on
    August 6, 2024, shall be entitled to receive notice of and to vote at the General Meeting.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Board of Directors recommends that you vote FOR the proposals, as specified in the form of proxy provided.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Whether or not you plan to attend the General Meeting, it is important that your ADSs be represented. Accordingly, you are kindly requested to complete, date, sign and mail the
    proxy in the envelope provided at your earliest convenience so that it will be received no later than four hours prior to the General Meeting. Execution of a proxy will not in any way affect a shareholder&#8217;s right to attend the General Meeting and vote
    in person, and any person giving a proxy has the right to revoke it at any time before it is exercised. ADS holders should return their proxies by the date set forth on their form of proxy.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders wishing to express their position on an agenda item for this General Meeting may do so by submitting a written statement (&#8220;<u>Position Statement</u>&#8221;) to the Company&#8217;s
    offices, c/o Mr. Razi Ingber, at 21 Ha&#8217;arba&#8217;a Street, Tel-Aviv, 6473921 Israel, by no later than Monday, September 7, 2024. Any Position Statement received that is in accordance with the guidelines set by the Israel Companies Law, will be furnished to
    the U.S. Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) on Form 6-K and will be made available to the public on the Commission&#8217;s website at <u>http://www.sec.gov</u>.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">&#160;If within half an hour from the time appointed for the General Meeting, a quorum is not present, the General Meeting shall be adjourned to the next business day following the day
    of the scheduled General Meeting, at the same time and place, or at another day, time and place prescribed by the Board of Directors in a notification to the shareholders.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">This Notice and the documents mentioned therein, as well as the proposed resolution on the agenda, can be viewed at the Company&#8217;s registered office on 21 Ha&#8217;arba&#8217;a Street,
    Tel-Aviv, Israel, Tel: +972 3 541 3131, Sunday through Thursday between 10:00-15:00, and also will be made available to the public on the Company's website at <u>http://www.redhillbio.com</u> and on the Commission&#8217;s website at <u>http://www.sec.gov.</u></div>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="zb3bb2b46a72d4fd89b1f1b1b35f126e9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 49.99%; vertical-align: top;"><br>
        </td>
        <td style="width: 50.01%; vertical-align: top;">
          <div style="line-height: 1.25;">By Order of the Board of Directors,</div>
        </td>
      </tr>
      <tr>
        <td style="width: 49.99%; vertical-align: top;">&#160;</td>
        <td style="width: 50.01%; vertical-align: top;">
          <div style="line-height: 1.25;">Dror Ben-Asher</div>
        </td>
      </tr>
      <tr>
        <td style="width: 49.99%; vertical-align: top;">&#160;</td>
        <td style="width: 50.01%; vertical-align: top;">
          <div style="line-height: 1.25;">Chairman of the Board of Directors</div>
        </td>
      </tr>

  </table>
  <div style="text-align: justify; line-height: 1.25;">Tel-Aviv, Israel</div>
  <div style="line-height: 1.25;">August 13, 2024</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <!--PROfilePageNumberReset%Num%2%%%-->
  <div style="text-align: center; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">REDHILL BIOPHARMA LTD.<br>
    </font><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">21 Ha&#8217;arba&#8217;a Street</div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Tel-Aviv 6473921</div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Israel</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PROXY STATEMENT<br style="line-height: 1.25;">
    <br>
    FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS</div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">To Be Held on September 17, 2024</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Proxy Statement is furnished to the holders of ordinary shares, par value NIS 0.01 per share (the &#8220;<u>Ordinary Shares</u>&#8221;), and to holders of American Depository Shares (&#8220;<u>ADSs</u>&#8221;),








    evidenced by American Depositary Receipts issued by The Bank of New York Mellon (&#8220;<u>BNY Mellon</u>&#8221;), of RedHill Biopharma Ltd. (the &#8220;<u>Company</u>&#8221; or &#8220;<u>RedHill</u>&#8221;) in connection with the solicitation by the board of directors of the Company
    (the &#8220;<u>Board of Directors</u>&#8221; or the &#8220;<u>Board</u>&#8221;) of proxies for use at the Annual General Meeting of Shareholders (the &#8220;<u>General Meeting</u>&#8221;), to be held on Tuesday, September 17, 2024, at 15:00 p.m. Israel time at the offices of the Company,
    21 Ha&#8217;arba&#8217;a Street, Tel-Aviv, Israel, or at any adjournments thereof.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25;">It is proposed at the General Meeting to adopt the following proposals or to consider the following items:</div>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="z0c447343b42b45179ecbbf1ec8ba7afc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">1.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To appoint Kesselman &amp; Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company&#8217;s auditors for the year 2024 and for an additional period until the next Annual General
            Meeting; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2023;</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="z93cba131c8e94165b2fa88df2620c03d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">2.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To approve the re-election of Mr. Eric Swenden and Mr. Ofer Tsimchi and the election of Dr. Roni Mamluk to the board of directors of the Company (the &#8220;<u>Board of Directors</u>&#8221;) for an additional three-year term until the annual general
            meeting to be held in 2027;</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="za005fed3db804d56b51c9c3585a7d048" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">3.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To approve the grant of restricted share units (&#8220;<u>RSUs</u>&#8221;) each with respect to one American Depository Shares (each representing 400 ordinary shares, par value NIS 0.01 each) (&#8220;<u>ADSs</u>&#8221;) to the non-executive directors of the
            Company;</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="ze7a2a667664441708a0228c2bdb5cf10" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">4.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors; and</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" id="z587797329e064f5db8713dcebb1bc024" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 8.5pt;"><br>
        </td>
        <td style="width: 19.85pt; vertical-align: top;">5.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company&#8217;s Chief Commercial Officer, and Director.</div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In addition, shareholders at the General Meeting will have an opportunity to review and ask questions regarding the financial statements of the Company for the fiscal year ended
    December 31, 2023.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Company is currently unaware of any other matters that may be raised at the General Meeting. Should any other matters be properly raised at the General Meeting, the persons
    designated as proxies shall vote according to their own judgment on those matters.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Shareholders may present proposals for consideration at the General Meeting by submitting their proposals to the Company no later than August 13, 2024, in accordance with
    applicable law.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Shareholders Entitled to Vote</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Only holders of ADSs of record at the close of business on August 6, 2024, shall be entitled to receive notice of and to vote at the General Meeting. At the close of business on
    August 6, 2024, the Company had outstanding 12,805,391,000 Ordinary Shares (represented 32,013,477 ADSs), each of which is entitled to one vote on the matters to be presented at the General Meeting.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Proxies</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A form of proxy card for use at the General Meeting is attached to this Proxy Statement and has been sent to the holders of ADSs together with a prepaid return envelope for the
    proxy. By executing the proxy card and appointing &#8220;proxies&#8221;, holders of ADSs may vote at the General Meeting, whether or not they attend.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">ADS holders should return their proxies in the enclosed form to BNY Mellon by the date set forth on the proxy card. If a properly executed proxy is received by BNY Mellon by the date
    set forth on the proxy card, all of the Ordinary Shares represented by the proxy shall be voted as indicated on the proxy card.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to applicable law and the rules of the NASDAQ Stock Market (&#8220;<u>NASDAQ</u>&#8221;), in the absence of instructions, the ADSs represented by properly executed and received proxies
    will be voted FOR all of the proposed resolutions to be presented at the General Meeting for which the Board of Directors recommends a &#8220;FOR&#8221;. Holders of ADSs may revoke their proxies at any time before the deadline for receipt of proxies by filing with
    BNY Mellon a written notice of revocation or duly executed proxy bearing a later date.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Expenses and Solicitation</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Board of Directors is soliciting proxies for use at the General Meeting. The Company expects to mail this Proxy Statement and the accompanying proxy cards to ADS holders on or
    about August 13, 2024. In addition to the solicitation of proxies to holders of ADSs by mail, certain officers, directors, employees and agents of the Company may solicit proxies by telephone, mail or other personal contact. The Company shall bear the
    cost of the solicitation of the proxies, including postage, printing and handling and shall reimburse the reasonable expenses of brokerage firms and others for forwarding materials to beneficial owners of ADSs. In addition, we have retained Kingsdale
    Advisors (&#8220;<u>Kingsdale</u>&#8221;) to assist in the solicitation of proxies.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This proxy statement and proxy card shall also serve as a voting deed (ktav hatzba&#8217;a), as such term is defined under the Israel Companies Law 1999 (the &#8220;<u>Companies Law</u>&#8221;).</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Quorum and Voting</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">Two or more shareholders holding ADSs or Ordinary Shares conferring in the aggregate at least twenty-five percent (25%) of the voting power of the Company,
      present in person or by proxy at the General Meeting and entitled to vote thereat, shall constitute a quorum. If within half an hour from the time appointed for the General Meeting, a quorum is not present, the General Meeting shall be adjourned to
      the next business day following the day of the scheduled meeting, at the same time and place, or at such other day, time and place as shall be prescribed by the Board of Directors in a notification to the shareholders. At such reconvened meeting, any
      one (1) shareholder present in person or by proxy shall constitute a quorum regardless of the number of Ordinary Shares represented.</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;"> <br>
    </div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The approval of Proposals 1, 2, 3 and 5 each requires the affirmative vote of at least a majority of the voting power represented at the General Meeting, in person or by proxy, and
    voting on the matter presented.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, the approval of Proposal 4 requires the affirmative vote of at least a majority of the voting power represented at the General Meeting, in person or by proxy, and voting
    on the matter presented, provided that either: (i) such majority vote at the General Meeting shall include at least a majority of the total votes of shareholders who are not controlling shareholders of the Company (as defined in the Companies Law) and
    do not have a personal interest in the approval of the proposal, participating in the voting at the General Meeting, in person or by proxy, without taking abstentions into account; or (ii) the total number of votes of the non-controlling shareholders
    mentioned in clause (i) above that are voted against such proposal does not exceed two percent (2%) of the total voting rights in the Company.</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
    <div style="text-align: left; line-height: 1.25;"><br>
    </div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
    <div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times-Roman,'Times New Roman';">For this purpose, a &#8220;Controlling shareholder&#8221; is any shareholder that has the ability to direct the Company&#8217;s activities (other than by means of being a
      director or other office holder of the Company). A person is presumed to be a controlling shareholder if the person holds or controls, alone or together with others, one-half or more of any one of the &#8220;means of control&#8221; of the Company. &#8220;Means of
      control&#8221; is defined as any one of the following: (i) the right to vote at a general meeting of the Company or (ii) the right to appoint directors of the Company or its chief executive officer.</div>
  </div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">In addition, for this purpose, &#8220;personal interest&#8221; is defined under the Companies Law as: (1) a shareholder&#8217;s personal interest in the approval of an act or a
      transaction of the Company, including (i) the personal interest of any of his or her relatives (which includes for these purposes the foregoing shareholder&#8217;s spouse, siblings, parents, grandparents, descendants, and spouse&#8217;s descendants, siblings,
      and parents, and the spouse of any of the foregoing); (ii) a personal interest of a corporation in which a shareholder or any of his/her aforementioned relatives serve as a director or the Chief Executive Officer, owns at least 5% of its issued share
      capital or its voting rights or has the right to appoint a director or Chief Executive Officer; and (iii) a personal interest of an individual voting via a power of attorney given by a third party (even if the empowering shareholder has no personal
      interest), and the vote of an attorney-in-fact shall be considered a personal interest vote if the empowering shareholder has a personal interest, and all with no regard as to whether the attorney-in-fact has voting discretion or not, but (2)
      excludes a personal interest arising solely from the fact of holding shares in the Company.</div>
  </div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">Please note that you are required to indicate on the proxy card with respect to Proposal 4 whether you are a controlling shareholder of the Company, or acting
    on its behalf or not, and whether you have a personal interest in the approval of Proposal 4 or not. If you fail to so indicate on the proxy card, your vote may not be counted with respect to the proposal for which you failed to provide notification.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="font-weight: bold;">A shareholder must inform our Company before the vote whether or not such shareholder is a controlling shareholder or has a personal interest. To
      avoid confusion, every shareholder voting by means of the enclosed proxy card or voting instruction form, or via telephone or internet voting</font>,&#160;<font style="font-weight: bold;">will be deemed to confirm to the Company that such shareholder is
      NOT a controlling shareholder and DOES NOT have a personal interest in Proposal 4</font>.&#160;<font style="font-weight: bold;">If you, or a related party of yours, is a controlling shareholder or possesses a personal interest and you wish to participate
      in the vote on Proposal 4&#160;(in which case your vote will only count for or against the ordinary majority, and not for or against the Special Majority required for approval of Proposal 4)</font>,&#160;<font style="font-weight: bold;">please notify Avshalom
      Lavski, the Company&#8217;s Executive Director of Legal Affairs &amp; Capital Markets, by telephone at phone number +972 3 541 3131 or by email at <u>avshi@redhillbio.com</u>. If you hold your shares in&#160;</font>&#8220;<font style="font-weight: bold;">street name</font>&#8221;<font style="font-weight: bold;">&#160;(i.e., shares that are held through a bank, broker or other nominee) and you are a controlling shareholder or possess a personal interest in the approval of Proposal 4, you may also contact the representative managing your
      account of that status, and they in turn should notify the Company as described in the preceding sentence.</font></div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Shareholders wishing to express their position on an agenda item for this General Meeting may do so by submitting a written statement (&#8220;<u>Position Statement</u>&#8221;) to the
    Company&#8217;s offices, c/o Mr. Razi Ingber at 21 Ha&#8217;arba&#8217;a Street, Tel-Aviv, 6473921 Israel. Any Position Statement received, that is in accordance with the guidelines set by the Israel Companies Law, will be furnished to the U.S. Securities and Exchange
    Commission (the &#8220;Commission&#8221;) on Form 6-K, and will be made available to the public on the Commission&#8217;s website at <u>http://www.sec.gov</u>.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Position Statements must be submitted to the Company by no later than September 7, 2024.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The rate of participation of each director in the Board of Directors meetings held during 2023 (for meetings held while each served as a member of the Board) was as follows: (i) Dror
    Ben-Asher &#8211; 100%, (ii) Eric Swenden &#8211; 60%, (iii) Ofer Tsimchi &#8211; 84%, (iv) Dr. Kenneth Reed &#8211; 100%, (v) Rick D. Scruggs &#8211; 96%, (vi) Dr.&#160;Shmuel Cabilly &#8211; 80%, and (vii) Alla Felder &#8211; 96% (served until June 4, 2024). The rate of participation of each
    director in the Board of Directors meetings held during 2022 (for meetings held while each served as a member of the Board) was as follows: (i) Dror Ben-Asher &#8211; 100%, (ii) Eric Swenden &#8211; 63%, (iii) Ofer Tsimchi &#8211; 100%, (iv) Dr. Kenneth Reed &#8211; 92%, (v)
    Rick D. Scruggs &#8211; 100%, , (vi) Dr.&#160;Shmuel Cabilly &#8211; 92%,(vii)&#160;Alla Felder &#8211; 96%.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The rate of participation of each member of the audit committee of the Board of Directors (the &#8220;<u>Audit</u>&#160;<u>Committee</u>&#8221;) in the Audit Committee meetings during 2023 (for
    meetings held while each served as a member of the committee) was as follows: (i) Eric Swenden &#8211; 67%, (ii) Ofer Tsimchi &#8211; 100%, (iii) Dr. Kenneth Reed &#8211; 100%,&#160; and (iv) Alla Felder &#8211; 100% and during 2022 was as follows: (i) Eric Swenden &#8211; 73%, (ii)
    Ofer Tsimchi &#8211; 100% and (iii) Alla Felder &#8211; 100%.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The rate of participation of the members of the compensation committee of the Board of Directors (the &#8220;<u>Compensation Committee</u>&#8221;) in the Compensation Committee meetings during
    2023 (for meetings held while each served as a member of the committee) was as follows: (i) Dr. Kenneth Reed &#8211; 100%, (ii) Ofer Tsimchi &#8211; 100% and (iii) Alla Felder &#8211; 100%, and for 2022 was as follows: (i) Dr. Kenneth Reed &#8211; 100%, (ii) Ofer Tsimchi &#8211;
    100% and (iii) Alla Felder &#8211; 86%.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All of our directors are independent other than Mr. Dror Ben-Asher and Mr. Rick D. Scruggs.</div>
  <br>
  <div style="line-height: 1.25; font-weight: bold;">Reporting Requirements</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Company is subject to the information reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;<u>Exchange Act</u>&#8221;), applicable to foreign private
    issuers. The Company fulfills these requirements by filing reports with the Commission. The Company&#8217;s filings are available to the public on the Commission&#8217;s website at <u>http://www.sec.gov</u>.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a foreign private issuer, the Company is exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements. The circulation of this notice and
    proxy statement should not be considered as an admission that the Company is subject to the proxy rules under the Exchange Act.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 28.35pt; margin-right: 1.7pt; line-height: 1.25;">THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE <font style="font-weight: bold; font-style: italic;">FOR</font> EACH OF THE PROPOSALS.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as specifically provided herein, the lack of a required majority for the adoption of any resolution presented shall not affect the adoption of any other resolutions for which
    the required majority was obtained.</div>
  <div style="line-height: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" border="0" id="z04ef292f1f8d4cda83e78110c4198b94" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 100%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 36pt; margin-right: 1.45pt; line-height: 1.25; font-weight: bold;"> <br>
            </div>
            <div style="text-align: justify; text-indent: 36pt; margin-right: 1.45pt; line-height: 1.25; font-weight: bold;">We request you to carefully read this entire Proxy Statement, including the documents we refer to in this Proxy Statement. If you
              have any questions, need assistance in voting, or need additional material, please contact our Strategic Shareholder Advisor and Proxy Solicitation Agent, Kingsdale Advisors:</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">North American Toll-Free Phone:&#160;+1-866-229-8166</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">Text or Call Collect Outside North America: +1-646-386-1025</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">Email: <u>contactus@kingsdaleadvisors.com</u></div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u> <br>
            </u></div>
        </td>
      </tr>

  </table>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PROPOSAL NO. 1</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">APPOINTMENT OF AUDITORS</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and the Company&#8217;s Amended and Restated Articles of Association (the &#8220;<u>Articles</u>&#8221;), the shareholders of the Company are authorized to appoint the
    Company&#8217;s independent auditors. Under the Articles, the Board of Directors, following receipt of the recommendation of the Audit Committee, is authorized to determine the independent auditors&#8217; remuneration. In addition, the Listing Rules of NASDAQ
    require that the Audit Committee approve the re-appointment and remuneration of the independent auditors.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the General Meeting, shareholders will be asked to approve the re-appointment of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers
    International Limited, an independent registered public accounting firm, as the Company&#8217;s auditors for the year ending December 31, 2024 and for an additional period until the next Annual General Meeting. Kesselman &amp; Kesselman has no relationship
    with the Company or with any affiliate of the Company except to provide audit services and tax consulting services.</div>
  <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Information on fees paid to the Company&#8217;s independent auditors may be found in the Company&#8217;s Annual Report on Form 20-F filed with the Securities and Exchange Commission.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">It is proposed that at the General Meeting, the following resolution be adopted:</div>
  <div style="text-align: justify; text-indent: 21.3pt; line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; margin-right: 1.35pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">RESOLVED,</font>&#160;<font style="font-weight: bold; font-style: italic;">that Kesselman &amp; Kesselman
      be, and hereby is, appointed as the auditors of the Company for the year 2024 and for an additional period until the next annual general meeting.</font><font style="font-weight: bold;">&#8221;</font></div>
  <div style="text-align: justify; margin-right: 29.8pt; margin-left: 35.45pt; line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of at least a majority of the voting power represented at the General Meeting, in person or by proxy and voting thereon, is required to adopt this resolution.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">THE COMPANY&#8217;S BOARD OF DIRECTORS RECOMMEND A VOTE FOR APPROVAL OF THIS RESOLUTION.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PROPOSAL NO. 2</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">RE-ELECTION OF MR. ERIC SWENDEN AND MR. OFER TSIMCHI AS DIRECTORS AND </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">ELECTION OF DR. RONI MAMLUK AS A DIRECTOR</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">According to the Articles, the Company&#8217;s directors are divided into three groups with as&#160;nearly equal in number of directors as practicable. The term of one group of directors
    expires at each annual general meeting, at which time the directors of such group are re-nominated to serve an additional three-year term that expires at the annual general meeting held in the third year following such election.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The current members of the first group are Mr. Eric Swenden and Mr. Ofer Tsimchi, whose terms expire as of the General Meeting. The members of the second group, currently consisting
    of Mr. Dror Ben-Asher and Dr. Kenneth Reed, will hold office until our annual general meeting to be held in the&#160;year 2025, and the members of the third group, currently consisting of Dr. Shmuel Cabilly and Mr. Rick D. Scruggs, will hold office until
    our annual general meeting to be held in the&#160;year 2026. The Company is proposing that Mr. Eric Swenden and Mr. Ofer Tsimchi each be re-elected, and that Dr. Roni Mamluk be elected, for a three-year term as part of the first group.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Proxies (other than those directing the proxy holders not to vote for the listed nominees) will be voted for the election of each of the nominees to hold office until the annual
    general meeting to be held in 2027, or such earlier time as they may resign or be removed from the Board of Directors, all pursuant to the terms of the Articles. The Company is not aware of any reason why any of the nominees, if elected, should not be
    able to serve as a director.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each of Mr. Eric Swenden, Mr. Ofer Tsimchi and Dr. Roni Mamluk has attested to the Board of Directors and to the Company that s/he meets all the requirements in connection with the
    election of directors under the Companies Law.</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;The nominees to serve on the Board of Directors are below and the following information with respect to each nominee is supplied based upon the information furnished to the Company
    by the respective nominee:</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="font-style: italic;">Eric Swenden </font>has served as a member of our board of directors since May 2010 and has served on our investment committee since May 2011.
    From 1966 until 2001 Mr. Swenden served in various positions including Chief Executive Officer (since 1985) and Executive Chairman (since 1990) of Vandemoortele Food Group, a privately held Belgium-based European food group with revenue of
    approximately EUR 2 billion. Mr. Swenden holds an M.A. in Commercial Science from the University of Antwerp, Belgium. The board of directors has determined that Mr. Swenden is a financial and accounting expert under Israeli law.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="font-style: italic;">Ofer Tsimchi </font>has served as a director on our board of directors, a member of our audit committee and as the Chairman of our compensation
    committee since May 2011. From 2008 to 2012, Mr. Tsimchi served as the Chairman of the board of directors of Polysack Plastic Industries Ltd. and Polysack-Agriculture Products, served as a board member of Caesarstone Ltd. and Danbar Group Ltd and since
    2006, he has served as a Partner in the Danbar Group Ltd., a holding company. Mr. Tsimchi currently serves on the board of directors of Maabarot Products Ltd. Mr. Tsimchi received his BA in Economics and Agriculture from the Hebrew University of
    Jerusalem, Israel. The board of directors has determined that Mr. Tsimchi is a financial and accounting expert under Israeli law.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Dr. Mamluk </font>currently serves as the Chairperson of OffRa Health, a healthcare AI company, and as a consultant to the Israeli government for
    Ag-tech in the Gaza Envelop region. Dr. Mamluk served as a board member at Amryt Pharma plc (previously Nasdaq-listed) between 2021-2023 and as a board member at Chiasma between 2013-2021. From 2017 to 2023, Dr. Mamluk was a co-founder and served as
    President and Chief Executive Officer of Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage precision oncology company. From 2006 to 2017, Dr. Mamluk served in various management roles at Chiasma, a biopharmaceutical company, including as Chief
    Development Officer and Chief Executive Officer. Dr. Mamluk received a Ph.D., Summa Cum Laude, from The Hebrew University in Jerusalem, the Department of Animal Sciences.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; margin-right: 1.35pt; line-height: 1.25; font-style: italic; font-weight: bold;">&#8220;RESOLVED, that Mr. Ofer Tsimchi and Mr. Eric Swenden each be re-elected, and Dr. Roni Mamluk be, and hereby is,
    elected, to hold office as a director of the Company, each for a three-year term until the annual general meeting to be held in 2027 or unless earlier expired in accordance with the Company's Articles of Association.&#8221;</div>
  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of at least a majority of the voting power represented at the General Meeting, in person or by proxy and voting thereon, is required to adopt this resolution.</div>
  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE RE-ELECTION AND ELECTION OF THE NOMINEES TO THE BOARD OF DIRECTORS. </div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PROPOSAL NO. 3</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">GRANT OF RSUs TO THE NON-EXECUTIVE DIRECTORS OF THE COMPANY</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">It is proposed to grant RSUs each with respect to one ADS of the Company to each of the following Company non-executive directors: Mr. Eric Swenden, Dr. Kenneth Reed, Mr. Ofer
    Tsimchi and Dr. Shmuel Cabilly (with respect to Mr. Eric Swenden and Mr. Ofer Tsimchi,&#160;subject to their re-election as members of the Board, as provided in this Proxy Statement).</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The proposal would grant to: (i) each of Dr. Shmuel Cabilly and Dr. Kenneth Reed RSUs with respect to 34,000 ADSs of the Company, (ii) Mr. Eric Swenden RSUs with respect to 38,000
    ADSs of the Company and (iii) Mr. Ofer Tsimchi RSUs with respect to 50,000 ADSs of the Company. Mr. Swenden serves on the Company&#8217;s audit committee, and Mr. Tsimchi serves on the Company&#8217;s audit committee and compensation committee.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35pt; margin-right: 1.45pt; margin-left: 1pt; line-height: 1.25;">The Compensation Committee and Board of Directors have approved the proposed grant of RSUs in light of each such non-executive director's
    contribution and anticipated contribution to the Company. The proposed grants comply with the principles of the Compensation Policy. The purpose of the grant is, <font style="font-style: italic;">inter alia,</font> to compensate each such director for
    his service and contribution to the Company as well as to provide an equity incentive to continue to contribute to the Company's success and results of operations.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The RSUs would vest quarterly over two (2) years in eight (8) equal parts. The vesting commencement date of each of Mr. Eric Swenden Dr. Kenneth Reed, Mr. Ofer Tsimchi and Dr.
    Shmuel Cabilly would be as of June 24, 2024, and the RSUs would become fully vested, in accordance with the terms of the grant, on March 31, 2026.</div>
  <div style="line-height: 1.25;">
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
  </div>
  <div style="line-height: 1.25;">
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">&#160;The equity grants and related terms would be in accordance with the Company&#8217;s Amended and Restated Award Plan (2010), as amended. The proposed equity grant to: (i) each of Dr.
      Shmuel Cabilly and Dr. Kenneth Reed represented approximately 0.07% of the total outstanding equity of the Company on a fully diluted basis as of the date of approval by the Board of Directors, (ii) Mr. Eric Swenden represented approximately 0.08% of
      the total outstanding equity of the Company on a fully diluted basis as of the date of approval by the Board of Directors, and, (iii) Mr. Ofer Tsimchi represented approximately 0.11% of the total outstanding equity of the Company on a fully diluted
      basis as of the date of approval by the Board of Directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The background and qualifications of Mr. Ofer Tsimchi and Mr. Eric Swenden are described in Proposal 2 of this Proxy Statement. Below are summaries of the background and
    qualifications of Dr. Kenneth Reed and Dr. Shmuel Cabilly.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Dr. Kenneth Reed</font>&#160;has served as a member of our board of directors since December 2009. Dr. Reed is a dermatologist practicing in private
    practice under the name of Kenneth Reed M.D. PC. Dr. Reed currently serves on the board of directors of Minerva Biotechnologies Corporation. Dr. Reed received his B.A. from Brown University in the U.S. and an M.D from the University of Medicine and
    Dentistry of New Jersey in the U.S. Dr. Reed is a board-certified dermatologist with over 25 years of clinical experience since completing the Harvard Medical School Residency Program in Dermatology. Dr. Reed is also a co-founder of Early Cell, a
    prenatal diagnostics company, Prescient Pharma and Lispiro.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="font-style: italic;">Dr. Shmuel Cabilly</font>&#160;has served as a member of our board of directors since August 2010. Dr. Cabilly is a scientist and inventor in the
    field of immunology. In the Backman Research Institute of the City of Hope, Dr. Cabilly initiated the development of a new breakthrough technology for recombinant antibody production, which was patented and known as the &#8220;Cabilly Patent.&#8221; Dr. Cabilly
    was also a co-founder and a Chief Scientist of Ethrog Biotechnology, where he invented dry buffer technologies enabling the production of a liquid-free disposable apparatus for gel electrophoresis and a technology that enables the condensation of
    molecular separation zones to a small gel area. This technology was sold to Invitrogen in 2001. Dr. Cabilly serves as a board member at several companies, including BioKine Therapeutics Ltd., and Minovia Ltd. Dr. Cabilly holds a B.Sc. in Biology from
    the Ben Gurion University of Beer Sheva, Israel, an M.Sc. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel, and a Ph.D. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: -0.55pt; margin-left: 36pt; line-height: 1.25;">It is proposed that at the General Meeting, the following resolution be adopted:</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">&#8220;RESOLVED, to approve the grant of RSUs to the non-executive directors of the Company on the terms described in the proxy statement.&#8221;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of at least a majority of the voting power represented at the General Meeting, in person or by proxy and voting thereon, is required to adopt this resolution.</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">THE COMPENSATION COMMITTEE AND THE BOARD OF DIRECTORS RECOMMEND THAT YOU VOTE FOR THE APPROVAL OF THE RSUs GRANTS TO THE NON-EXECUTIVE DIRECTORS OF THE COMPANY.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PROPOSAL NO. 4&#160;</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">GRANT OF RSUs OF THE COMPANY TO MR. DROR BEN-ASHER</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35pt; margin-right: 1.45pt; margin-left: 1pt; line-height: 1.25;">The Companies Law requires that the terms of service and employment of a company&#8217;s Chief Executive Officer be approved by the company&#8217;s
    compensation committee, the board of directors and the shareholders of the company, except in the limited circumstances set forth in the Companies Law.&#160;In addition, the Companies Law provides that transactions between a company and its directors
    regarding their terms of office as directors, and with respect to their terms of employment in other positions in the company, are subject to the approval of such company&#8217;s audit committee or compensation committee, as applicable, board of directors
    and shareholders.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35pt; margin-right: 1.45pt; margin-left: 1pt; line-height: 1.25;"><font style="font-style: italic;">Mr. Dror Ben-Asher</font> has served as the Company&#8217;s Chief Executive Officer since its incorporation and
    has served as the Chairman of the Board of Directors for substantially all of the time during that period. In light of Mr. Ben-Asher&#8217;s contribution to the Company, and in accordance with the Company&#8217;s Compensation Policy, the Board of Directors and
    Compensation Committee have determined that the proposed grants of RSUs with respect to 127,000 ADSs is appropriate, reasonable and reflect the significant contribution of Mr. Ben-Asher to the Company.</div>
  <div style="text-align: justify; text-indent: 35pt; margin-right: 1.45pt; margin-left: 1pt; line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The RSUs would vest quarterly over two (2) years. The vesting commencement date would be as of June 24, 2024, and the RSUs would become fully vested, in accordance with the terms of
    the grant, on March 31, 2026.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The equity grant would be in accordance with the Plan, and the remaining terms of the equity grant would be in accordance with such plan. The proposed equity grant represents 0.27%
    of the total outstanding equity of the Company on a fully diluted basis,&#160;as of the date of approval by the Board of Directors.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The purpose of the grant is, <font style="font-style: italic;">inter alia</font>, to compensate Mr. Ben-Asher for his service and his continual contribution to the Company as well
    as to incentivize Mr. Ben-Asher to continue to contribute to the Company&#8217;s success and results of operations.</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">It is proposed that at the General Meeting the following resolution be adopted:</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">&#8220;RESOLVED, to approve the grant of RSUs to Mr. Dror Ben-Asher on the terms described in the proxy statement</font>.<font style="font-weight: bold; font-style: italic;">&#8221;</font></div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The affirmative vote of at least a majority of the voting power represented at the General Meeting, in person or by proxy, and voting on the matter presented, is required for
    shareholders to approve this resolution provided that either: (i) such majority vote at the General Meeting shall include at least a majority of the total votes of shareholders who are not controlling shareholders of the Company (as defined in the
    Companies Law) and do not have a personal interest in the approval of the proposal, participating in the voting at the General Meeting, in person or by proxy, without taking abstentions into account; or (ii) the total number of votes of the
    non-controlling shareholders mentioned in clause (i) above that are voted against such proposal does not exceed two percent (2%) of the total voting rights in the Company.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">THE COMPENSATION COMMITTEE AND THE BOARD OF DIRECTORS RECOMMEND A VOTE FOR THE APPROVAL OF THE GRANT OF RSUs TO MR. DROR BEN-ASHER.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PROPOSAL NO. 5&#160;</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">GRANT OF RSUs OF THE COMPANY TO MR. RICK D. SCRUGGS</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law requires that transactions between a company and its directors regarding their terms of office as director, and with respect to their terms of employment in other
    positions in the company, are subject to the approval of such company&#8217;s compensation committee, board of directors and shareholders.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Mr. Rick D. Scruggs</font> has served as a director of the Company since January 1, 2016, and since January 1, 2019, Mr. Scruggs has served as the
    Chief Operations Officer, U.S. Operations of the Company&#8217;s wholly-owned U.S. subsidiary, RedHill Biopharma Inc. and then became its Chief Commercial Officer. Mr. Scruggs has significant business development and commercial experience in the biopharma
    industry, including as the former Executive Vice President Business Development at Salix Pharmaceuticals.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Company&#8217;s Board of Directors and Compensation Committee approved and recommended that the Company&#8217;s shareholders to approve the grant of RSUs with respect to 100,000 ADSs of the
    Company to Mr. Scruggs.</div>
  <div style="line-height: 1.25">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The RSUs would vest quarterly over two (2) years. The vesting commencement date would be as of June 24, 2024, and the RSUs would become fully vested, in accordance with the terms of
    the grant, on March 31, 2026.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="line-height: 1.25;">
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The equity grants and related terms would be in accordance with the Plan. The proposed equity grant to Mr. Scruggs represented 0.21% of the total outstanding equity of the Company
      on a fully diluted basis on the date of approval by the Board of Directors.</div>
  </div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The purpose of the grant is, <font style="font-style: italic;">inter alia</font>, to compensate Mr. Scruggs for his service and his continual contribution to the Company as well as
    to incentivize Mr. Scruggs to continue to contribute to the Company's success and results of operations.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">It is proposed that at the General Meeting the following resolution be adopted:</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 35.45pt; margin-right: 0.45pt; line-height: 1.25; font-style: italic; font-weight: bold;">&#8220;RESOLVED, to approve the grant of RSUs to Mr. Rick D. Scruggs on the terms described in the proxy&#160;statement.&#8221;</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of at least a majority of the voting power represented at the General Meeting, in person or by proxy and voting thereon, is required to adopt this resolution.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">THE COMPENSATION COMMITTEE AND THE BOARD OF DIRECTORS RECOMMEND A VOTE FOR THE APPROVAL OF THE GRANT OF RSUs TO MR. RICK D. SCRUGGS.</div>
  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
  </div>
  <div style="line-height: 1.25; font-weight: bold;">By order of the Board of Directors</div>
  <div style="line-height: 1.25;">
    <div style="line-height: 1.25; font-weight: bold;">Dror Ben-Asher</div>
  </div>
  <div style="line-height: 1.25; font-weight: bold;">Chairman of the Board of Directors</div>
  <div style="line-height: 1.25; font-weight: bold;">Dated: August 13, 2023</div>
  <div style="line-height: 1.25">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="line-height: 1.25">
    <div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div>
          <div>
            <div style="line-height: 1.25; text-align: center;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 3%; vertical-align: top; background-color: #000000;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 44%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 3%; vertical-align: top; background-color: #000000;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 50%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25;">&#160;</div>
                    </td>
                  </tr>

              </table>
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 50%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 12pt;">
                        <div style="line-height: 1.25; font-size: 10pt;"><font style="font-size: 12pt; font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Annual
                            General Meeting of </font></div>
                      </div>
                    </td>
                    <td style="width: 5%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                    </td>
                    <td style="width: 44.96%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 12pt;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                            <div style="line-height: 1.25; font-size: 10pt;"><font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;"><font style="font-weight: bold;">Annual General Meeting of </font>RedHill Biopharma Ltd. </font><br>
                            </div>
                          </div>
                        </div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 50%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 12pt;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">RedHill Biopharma Ltd. </font></div>
                        </div>
                      </div>
                    </td>
                    <td style="width: 5%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                    </td>
                    <td style="width: 44.96%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 12pt;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;">
                              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">to be held on September 17, 2024</div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 50%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;">Date:&#160;&#160;&#160;&#160;&#160;&#160; September 17, 2024</div>
                    </td>
                    <td style="width: 5%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                    </td>
                    <td style="width: 44.96%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 12pt;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;">
                              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
                                <div style="line-height: 1.25;">For Holders as of August 6, 2024</div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 50%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; See Voting Instruction On Reverse Side.</div>
                    </td>
                    <td style="width: 5%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                    </td>
                    <td style="width: 44.96%; vertical-align: top;"> <br>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 50%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;"><font style="font-weight: bold;">Please make your marks like this: </font>&#9746; <font style="font-weight: bold;">Use pen only</font></div>
                    </td>
                    <td style="width: 5%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                    </td>
                    <td style="width: 44.96%; vertical-align: top;">
                      <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                    </td>
                  </tr>

              </table>
              <div>
                <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                    <tr>
                      <td style="width: 3.37%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 20%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 8.88%;">
                        <div style="text-align: center;"><font style="font-weight: bold;">For</font></div>
                      </td>
                      <td style="width: 8.88%;">
                        <div style="text-align: center;"><font style="font-weight: bold;">Against</font> <br>
                        </div>
                      </td>
                      <td style="width: 8.88%;">
                        <div style="text-align: center;"><font style="font-weight: bold;">Abstain</font> <br>
                        </div>
                      </td>
                      <td colspan="1" rowspan="18" style="width: 3.83%; text-align: center;"> <img src="image00001.jpg"> </td>
                      <td colspan="1" rowspan="17" style="width: 46%; text-align: center;">
                        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <img src="image00002.jpg"></div>
                        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 72pt; font-weight: bold;"><font style="font-weight: normal;">&#9679;</font> <font style="font-family: 'Times New Roman', Times, serif;">Mark, sign and date your Voting Instruction Form. </font></div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 72pt;">&#9679; <font style="font-weight: bold;">Detach your Voting Instruction Form.</font></div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 72pt;">&#9679; <font style="font-weight: bold;">Return your Voting Instruction Form in the </font></div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 72pt;">&#160;&#160;&#160; <font style="font-weight: bold;">postage-paid envelope provided.</font></div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
                        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
                          <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">All votes must be received by 12:00 p.m. EST, on September 12, 2024 </font></div>
                        </div>
                        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160; <br>
                        </div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><br>
                          <div style="line-height: 1.25; font-weight: bold; margin-left: 81pt;">
                            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;">PROXY TABULATOR FOR </font></div>
                            <div style="line-height: 1.25; font-weight: bold; color: rgb(109, 109, 109);">REDHILL BIOPHARMA LTD. </div>
                            <div style="line-height: 1.25; font-weight: bold; color: rgb(109, 109, 109);">P.O. BOX 8016 </div>
                            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><font style="color: rgb(109, 109, 109);">CARY, NC 27512-9903</font> </div>
                          </div>
                        </div>
                        <div style="text-align: left; margin-left: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
                        <div>&#160;</div>
                        <div>&#160;</div>
                        <div>&#160;</div>
                        <div>&#160;</div>
                        <div>&#160;</div>
                        <div>&#160;</div>
                        <div>&#160;</div>
                        <div> <br>
                        </div>
                        <div> <br>
                        </div>
                        <div> <br>
                        </div>
                        <div>&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;">
                        <div>1.</div>
                      </td>
                      <td rowspan="1" style="text-align: left; vertical-align: top; width: 20%;">
                        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: justify;">
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;">
                              <div style="line-height: 1.25;">
                                <div style="text-align: left; line-height: 1.25;">
                                  <div style="line-height: 1.25;">To appoint Kesselman &amp; Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company&#8217;s auditors for the year 2024 and for
                                    an additional period until the next Annual General Meeting; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2023; </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">
                        <div>&#9744;</div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">
                        <div>&#9744;</div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">
                        <div>&#9744; <br>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td rowspan="1" style="width: 3.37%;">&#160;</td>
                      <td rowspan="1" style="width: 20%; text-align: justify; vertical-align: top;">
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
                        </div>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: middle;"><br>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: middle;"><br>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: middle;">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;">2.<br>
                      </td>
                      <td style="text-align: left; vertical-align: top; width: 20%;" rowspan="1">
                        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the re-election of Mr. Eric Swenden and Mr. Ofer Tsimchi and the election of Dr. Roni Mamluk to the board of directors of the Company (the &#8220;<u>Board






                            of Directors</u>&#8221;) for an additional three-year term until the annual general meeting to be held in 2027; </div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: middle;"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: middle;"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: middle;"><br>
                      </td>
                    </tr>
                    <tr>
                      <td rowspan="1" style="width: 3.37%;">&#160;</td>
                      <td rowspan="1" style="width: 20%; text-align: justify;">
                        <div style="text-align: left; text-indent: -13pt; margin-left: 13pt; line-height: 1.25;"><br>
                        </div>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: middle;">&#160;</td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: middle;">&#160;</td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: middle;">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;"><br>
                      </td>
                      <td style="width: 20%; text-align: left; vertical-align: top;">
                        <div style="text-indent: -13pt; margin-left: 13pt; line-height: 1.25;">2A. Mr. Eric Swenden </div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 20%; text-align: left; vertical-align: top;" rowspan="1">
                        <div style="text-indent: -13pt; margin-left: 13pt; line-height: 1.25;"><br>
                        </div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 20%; text-align: left; vertical-align: top;" rowspan="1">2B. Mr. Ofer Tsimchi </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                    </tr>
                    <tr>
                      <td rowspan="1" style="width: 3.37%; text-align: left; vertical-align: top;"><br>
                      </td>
                      <td rowspan="1" style="width: 20%; text-align: justify; vertical-align: top;"><br>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: top; font-weight: bold;"><br>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: top;"><br>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: top;"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;"><br>
                      </td>
                      <td style="width: 20%; text-align: left; vertical-align: top;">2C. Dr. Roni Mamluk </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                    </tr>
                    <tr>
                      <td rowspan="1" style="width: 3.37%; text-align: left; vertical-align: top;"><br>
                      </td>
                      <td rowspan="1" style="width: 20%; text-align: justify; vertical-align: top;"><br>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: top;"><br>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: top;"><br>
                      </td>
                      <td rowspan="1" style="width: 8.88%; text-align: center; vertical-align: top;"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;">3.<br>
                      </td>
                      <td style="text-align: left; vertical-align: top; width: 20%;" rowspan="1">
                        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the grant of restricted share units (&#8220;<u>RSUs</u>&#8221;) each with respect to one American Depository Shares (each representing 400 ordinary shares,
                          par value NIS 0.01 each) (&#8220;<u>ADSs</u>&#8221;) to the non-executive directors of the Company; </div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;">&#9744; </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 20%; text-align: justify; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; font-weight: bold; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; font-weight: bold; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1">4.<br>
                      </td>
                      <td style="width: 20%; text-align: justify; vertical-align: top;" rowspan="1">
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors; and </div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"></div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 20%; text-align: justify; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1">5.<br>
                      </td>
                      <td style="text-align: left; vertical-align: top; width: 20%;" rowspan="1">
                        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve a grant of RSUs of the Company to Mr. Rick D. Scruggs, the Company&#8217;s Chief Commercial Officer, and Director. <br>
                        </div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1">&#9744; </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 20%; text-align: justify; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: bottom; font-weight: bold;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: bottom; font-weight: bold;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%;" rowspan="1"><br>
                      </td>
                    </tr>
                    <tr>
                      <td colspan="2" style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1">
                        <div style="line-height: 1.25;"><font style="font-weight: bold;">By executing this proxy card you will be deemed to confirm that you are NOT a Controlling Shareholder and do NOT have a Personal Interest (as such terms are defined in
                            the Proxy Statement) in the approval of Proposal 4. If you are a Controlling Shareholder or have a Personal Interest (in which case your vote will count only for or against the ordinary majority, and not for or against the
                            Special Majority, required for approval of Proposal 4), please notify the Company as described on the reverse side of this proxy card. </font></div>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%;" rowspan="1"><br>
                      </td>
                      <td colspan="1" style="width: 46%; text-align: center;"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 3.37%; text-align: left; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 20%; text-align: justify; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 8.88%; text-align: center; vertical-align: middle;" rowspan="1"><br>
                      </td>
                      <td colspan="1" rowspan="1" style="width: 3.83%; text-align: center;">&#160;</td>
                      <td colspan="1" rowspan="1" style="width: 46%; text-align: left;"><img src="image00003.jpg"> <br>
                      </td>
                    </tr>

                </table>
              </div>
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td rowspan="1" style="width: 2.99%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 39.87%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 12%; vertical-align: bottom;">&#160;</td>
                    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 24%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 2.99%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 39.87%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 8%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 12%; vertical-align: bottom;">
                      <div style="line-height: 1.25; font-weight: bold;">EVENT&#160;#</div>
                    </td>
                    <td style="width: 2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 24%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6%; vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 2.99%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 39.87%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 8%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 12%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160; </div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 24%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6%; vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 2.99%; vertical-align: top;"> <br>
                    </td>
                    <td style="width: 39.87%; vertical-align: top;"> <br>
                    </td>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 8%; vertical-align: top;"> <br>
                    </td>
                    <td style="width: 12%; vertical-align: bottom;">
                      <div style="line-height: 1.25; font-weight: bold;">CLIENT&#160;#</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 24%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6%; vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 2.99%; vertical-align: top; background-color: #000000;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 39.87%; vertical-align: bottom; text-align: center;">
                      <div style="line-height: 1.25; font-weight: bold;">
                        <div style="line-height: 1.25;"><font style="font-weight: bold;">Authorized Signatures - This section must be</font></div>
                      </div>
                    </td>
                    <td style="width: 3%; vertical-align: top; background-color: #000000;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 8%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 12%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 24%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6%; vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 2.99%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 39.87%; vertical-align: bottom; text-align: center;">
                      <div style="line-height: 1.25; font-weight: bold;">
                        <div style="line-height: 1.25;"><font style="font-weight: bold;">completed for your instructions to be executed.</font></div>
                      </div>
                    </td>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 8%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 12%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 24%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6%; vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 2.99%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 39.87%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 8%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 12%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 24%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6%; vertical-align: top;">&#160;</td>
                  </tr>

              </table>
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top; border-bottom: #000000 2px solid;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6.96%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top; border-bottom: #000000 2px solid;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
                    <td style="width: 46%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25;">Please Sign Here</div>
                    </td>
                    <td style="width: 6.96%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25;">Please Date Above</div>
                    </td>
                    <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
                    <td style="width: 46%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6.96%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
                    <td style="width: 46%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top; border-bottom: #000000 2px solid;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 6.96%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top; border-bottom: #000000 2px solid;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
                    <td style="width: 46%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25;">Please Sign Here</div>
                    </td>
                    <td style="width: 6.96%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 20%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25;">Please Date Above</div>
                    </td>
                    <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
                    <td style="width: 46%; vertical-align: top;"><br>
                    </td>
                  </tr>

              </table>
              <div> <font style="font-size: 1pt; color: rgb(255, 255, 255);">Please separate carefully at the perforation and return just this portion in the envelope provided.</font></div>
              <div> <br>
              </div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div style="text-align: left; line-height: 1.25;"> <br>
              </div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 52.94%; vertical-align: top;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REDHILL BIOPHARMA LTD. </div>
                      <div style="line-height: 1.25">&#160;</div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Instructions to The Bank of New York Mellon, as Depositary</div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Must be received prior to 12:00 p.m. EST on September 12, 2024) </div>
                    </td>
                    <td style="width: 40.06%; vertical-align: top;">
                      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 52.94%; vertical-align: top;">
                      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 40.06%; vertical-align: top;">
                      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 2%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#160;</div>
                    </td>
                    <td style="width: 52.94%; vertical-align: top;">
                      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The undersigned registered owner of American Depositary Shares hereby requests and instructs The Bank of New York Mellon, as Depositary,
                        to endeavor, in so far as practicable, to vote or cause to be voted the amount of Shares or other Deposited Securities represented by such Shares of <font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">RedHill






                          Biopharma Ltd. </font>registered in the name of the undersigned on the books of the Depositary as of the close of business on <font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">August 6, 2024 </font>at






                        the <font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Annual General Meeting </font>of the Shareholders of <font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">RedHill
                          Biopharma Ltd. </font>to be held on <font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">September 17, 2024 </font>or any postponement or adjournment thereof in respect of the resolutions specified on
                        the reverse.
                        <div style="line-height: 1.25; font-weight: bold;">
                          <div style="line-height: 1.25;">
                            <div>
                              <div>
                                <div style="line-height: 1.25; font-weight: bold;">
                                  <div style="line-height: 1.25">&#160;</div>
                                  <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">This Notice and the documents mentioned therein, including the Proxy Statement, as well as the proposed resolutions on the
                                    agenda, will be made available to the public on the Company&#8217;s website <u>http://www.redhillbio.com </u></div>
                                  <div style="line-height: 1.25">&#160;</div>
                                  <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NOTES: </div>
                                  <div style="line-height: 1.25">&#160;</div>
                                  <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">1. Please direct the Depositary how it is to vote by placing an &#8220;X&#8221; in the appropriate
                                    box opposite each agenda item. </div>
                                  <div style="line-height: 1.25">&#160;</div>
                                  <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2. If you do not vote or if your voting instructions are not received before the
                                    deadline, you will be deemed to have given a discretionary proxy to the Company to vote the shares represented by your ADRs pursuant to the terms and conditions of the ADRs and the Deposit Agreement under which they are
                                    issued. </div>
                                  <div style="line-height: 1.25">&#160;</div>
                                  <div style="line-height: 1.25; font-weight: bold;">Important Note: By executing this proxy card on the reverse side, the undersigned shareholder will be deemed to confirm that such shareholder is NOT a Controlling
                                    Shareholder and does NOT have a Personal Interest (as such terms are defined in the Proxy Statement) in the approval of Proposal 4. If you are a Controlling Shareholder or have a Personal Interest (in which case your
                                    vote will count only for or against the ordinary majority, and not for or against the Special Majority, required for approval of Proposal 4), please notify the Company&#8217;s Executive Director of Legal Affairs &amp; Capital
                                    Markets, Avshalom Lavski, at 972 3 541 3131 or by email at avshi@redhillbio.com who will advise you as to how to submit your vote for this proposal. If your shares are held in &#8220;street name&#8221; by your broker, bank or other
                                    nominee and you are a Controlling Shareholder or have a Personal Interest, you should notify your broker, bank or other nominee of that status, and they in turn should notify the Company as described in the preceding
                                    sentence. </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </td>
                    <td style="width: 40.06%; vertical-align: bottom; text-align: center;">
                      <div>
                        <div>
                          <div style="margin-left: 117pt;"><img src="image00004.jpg"> </div>
                        </div>
                      </div>
                    </td>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                    </td>
                  </tr>

              </table>
              <div style="text-align: left;"> <br>
              </div>
              <div style="text-align: left;">
                <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
            </div>
          </div>
        </div>
      </div>
      <div style="line-height: 1.25; font-size: 1pt; color: rgb(255, 255, 255);">PROXY TABULATOR FOR </div>
    </div>
  </div>
  <div style="line-height: 1.25;">
    <div style="line-height: 1.25;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" (= !0# 2(  A$! Q$!_\0
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M-G8IYRLM]>K<F;<RF,KAFQCY\DXX(&.!CM];NY=/T>^O+:W:ZF@A>5(%ZR,
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M5N\*2<_*64@'CFN+\$^!'\/>)C?Q:9HEA;F&3<;('S&:383'R@^1&5L'.2&
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;QNN,@K\TAVL#U!&<YSS76T4+0'J%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  = %$# 2(  A$! Q$!_\0
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M\'DZG96]W&.@FC#;?<9Z'Z5X1XQ^%VF65[,EFLNFB4ED>WP89>,?/"V4..X
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+EOZ[A8**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  Z *H# 2(  A$! Q$!_\0
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M5IK6TEG0/;614LJ%AG$ XR*]DKQOQU_R)'B'_L'7'_HIJ]DI#/)- _U6I?\
M86U'_P!+)JTZS- _U6I?]A;4?_2R:M.F(**** "BBB@ HHHH **** "BBB@
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M%_\ %4?\)?X:_P"AAT?_ ,#8O_BJ]DHI@>-_\)?X:_Z&'1__  -B_P#BJ/\
MA+_#7_0PZ/\ ^!L7_P 57LE% 'C?_"7^&O\ H8='_P# V+_XJC_A+_#7_0PZ
M/_X&Q?\ Q5>R44 >-_\ "7^&O^AAT?\ \#8O_BJ/^$O\-?\ 0PZ/_P"!L7_Q
M5>R44 >-_P#"7^&O^AAT?_P-B_\ BJ/^$O\ #7_0PZ/_ .!L7_Q5>R44 >-_
M\)?X:_Z&'1__  -B_P#BJ/\ A+_#7_0PZ/\ ^!L7_P 57LE% 'C?_"7^&O\
MH8='_P# V+_XJC_A+_#7_0PZ/_X&Q?\ Q5>R44 >-_\ "7^&O^AAT?\ \#8O
M_BJ/^$O\-?\ 0PZ/_P"!L7_Q5>R44 >-_P#"7^&O^AAT?_P-B_\ BJ/^$O\
M#7_0PZ/_ .!L7_Q5>R44 >!>,_%/A^X\'Z[#;Z[I4LTEA.B1I>1LS,8V   /
*))[5[[112 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" "* #H# 2(  A$! Q$!_\0
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M$4 @_6B.S?\ 6X/>QR7Q+6XMO%OVJVT^RO[P"UEMI ;B2YLUCD+/A8H)"B.
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M@*?,*DCD]*]-Z4^@NIQGC"YCTCQ%IFJW-O#?(T+VL5L;B&.82%E;=$)656)
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E&\,4^L:K<Z7 R-#ITS1&)-A!0%@@D8 @8#.>G.:Z>BBBX'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
